by Devin McLaughlin
Neoadjuvant therapy with olaparib showed feasibility for women with germline-mutant ovarian cancer, according to results of the NOW trial presented at Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.
Researchers observed favorable surgical outcomes — even … Read more
by Jason Harris
Botensilimab (AGEN1181) in combination with balstilimab (AGEN2034) induced durable responses in patients with resistant/refractory ovarian cancer, according to findings from the phase 1 C-800 study (NCT03860272) presented at the 2023 SGO Annual Meeting on Women’s Cancer.1… Read more
by Caroline Seymour
The combination of abemaciclib and fulvestrant led to encouraging responses when used as neoadjuvant therapy which translated to high complete gross resection rates in patients with advanced, low-grade serous ovarian, fallopian tube, and peritoneal carcinoma.
The combination
by Conor Killmurray
Eighty-percent of all patients treated with durvalumab and tremelimumab in combination with neoadjuvant chemotherapy at least had a partial response to treatment prior to the end of a phase 2 trial.
The use of dual immune checkpoint
… Read more
